Ibrutinib

Phase 3

Pharmacyclics, Inc. (PCYC)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Apr '27

PCYCPhase 2

Ibrutinib Phase 2 Est. Readout

Ibrutinib• Diffuse Large B Cell Lymphoma Relapsed40

Apr 2027~Confirmed

CT.gov

00%

Mar '27

PCYCPhase 3

Ibrutinib Phase 3 Est. Readout

Ibrutinib• Diffuse Large B Cell Lymphoma Relapsed23

Mar 2027~Confirmed

CT.gov

00%

Dec '26

PCYCPhase 3

Ibrutinib Phase 3 Est. Readout

Ibrutinib• Diffuse Large B Cell Lymphoma Relapsed700

Dec 2026~Confirmed

CT.gov

00%

Development History

Sep '26

PCYCPhase 2

Ibrutinib Phase 2 Est. Readout

Ibrutinib• Diffuse Large B Cell Lymphoma Relapsed30

Sep 2026~ConfirmedSTALE

CT.gov

00%

Competitive Landscape

0 competitors in Diffuse Large B Cell Lymphoma Relapsed

View Full Landscape

Drug Information

Target Indication

Diffuse Large B Cell Lymphoma Relapsed

Clinical Trial

NCT02142049

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

PCYC

Pharmacyclics, Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

MGdPhase 3

Metastatic Cancer

ChlorambucilPhase 3

Chronic Lymphocytic Leukemia

Ibrutinib Oral CapsulePhase 3

Follicular Lymphoma

Motexafin GadoliniumPhase 3

Brain Neoplasms

Next-line ibrutinibPhase 3

Chronic Lymphocytic Leukemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts